Chemokine receptors belong to the transmembrane G protein coupled receptor (GPCR) family. Although a major physiological role of chemokine receptors is for host defense by recruitment of lymphocytes to inflammatory sites, they are now found to be involved in more processes such as virus infection, tumor genesis and metastasis, and embryologic development. In this review, we show an overall picture of chemokine receptors in structure, signal transduction and modulation, physiological and pathological roles, and applying chemokine receptors for drug discovery.
INTRODUCTION
A superfamily of small proteins called chemokine (a neologism short for "chemotactic cytokines") has attracted much attention since the discovery of neutrophil activating peptide IL-8 about 16 years ago [1] . This family plays an important role in cell migration and trafficking [2] [3] [4] [5] . The number of this family grows so fast that approximately 50 chemokines in humans have been described to date [4] . Several names were assigned to each member of the chemokines according to different origin [6] . For example, IL-8 for interleukin-8, SDF-1 for stromal cell-derived factor-1, and RANTES for regulated on activation normal T cell expressed and secreted. A nomenclature rule for naming the chemokines was developed based on protein structure and a previous nomenclature for chemokine gene loci [6] . Now, Chemokines are divided into four subclasses based on the number and position of conserved cysteines in chemokine domain: C, CC, CXC and CX 3 C [2, 6] . CC, CXC and CX 3 C contain four conserved cysteines while C only contains two that correspond to the second and fourth cysteine in this group. CXC means there is one other residue between the first and second cysteine and CX 3 C means there are three residues between the first and second cysteine. Two disulfide bonds are formed between the first and the third, as well as the second and the fourth cysteine [3] . All of the chemokines share similar structure with a flexible N-terminal segment, followed by three antiparallel β-sheets (also called "Greek key") and an α-helical C-terminal [2, 3] . Although most chemokines have molecular weight within range from 8 to 12 kD, there are two exceptions (CX 3 CL1 and CXCL16) that have a multimodular structure consisting of transmembrane domain and a chemokine domain suspended by a mucin-like stalk [6, 7] . In addition to the classification according to structure, another classification for chemokines has also been used based on their physiological functions. The inflammatory/inducible category, which is important in innate and adaptive immune responses, is regulated by proinflammatory stimuli such as lipopolysaccharide and primary cytokines such as tumor necrosis factor. The homeostatic/constitutive category, which plays an important role in lymphocyte and dendritic cell trafficking in immune surveillance, is expressed constitutively [5, 6] . Probably due to duplication and divergence from an ancient chemokine gene, the CXC and CC chemokines are mainly clustered on human chromosomes 4 and 17 respectively. Typically, they belong to the inflammatory/inducible group [6] .
Chemokines exert their effects through interacting with their receptors: chemokine receptors. The chemokine family has been described in detail in several reviews [2] [3] [4] [5] . This review will discuss aspects of the structure, function and drug development for chemokine receptors.
CHEMOKINE RECEPTORS: STRUCTURE AND ACTIVATION
Chemokine receptors belong to the Class I or rhodopsinlike G protein coupled receptor (GPCR) superfamily. In humans, this superfamily consists of nearly 650 members [8] with a common structure, that is, an extracellular N terminal followed by seven transmembrane α-helixes connected by three extracellular loops and three intracellular loops and a cytoplasmic C-terminal tail [9] . The GPCR family is important in cell signaling by responding to divergent ligands such as photon, odor, small chemical molecules, small peptide, and big proteins [9] . In addition, this family also serves as a very important target in drug discovery. So far, 18 kinds of chemokine receptors have been discovered in humans with a broaden distribution in leukocytes [6, 7] . They are named according to the category of ligands they bind to: CXCR1-CXCR6, CCR1-CCR10, XCR1 and CX 3 CR1. Interestingly, like their ligands, most of chemokine receptors are also clustered in chromosomes, for example, CCR is in chromosome 3 and CXCR is in chromosome 2 [10] .
Overall Picture from Rhodopsin
Due to chemokine receptors containing seven highly hydrophobic transmembrane domains, it is difficult to get the structure based on the crystal of chemokine receptors. So far, much of our structure knowledge comes from the structure of a typical GPCR of this family: rhodopsin, which has been investigated for years and several structures with different resolutions are available. The transmembrane helices are seen organized in a counterclockwise fashion with transmembrane helix (TM) 3 being almost in the center of the molecule when determining the structure of frog rhodopsin by using electron micrographs [11] . TM4 and 7 are almost perpendicular to the plane of the membrane whereas TM1, 2, 3 and 5 are tilted [11] . TM6 is also almost perpendicular to the plane of the membrane in the cytoplasmic half but bending toward TM5 on the extracellular side [11] . The crystal structure with 2.8 angstroms resolution confirms this kind of counterclockwise fashion but provides more new insights for the structure [12] . For the transmembrane domain, more bends in the helices are found. According to the image, TM1, 4, 6, and 7 are bent at Pro residues especially there is a significant bend in TM6 [12] . In addition, TM2 is also kinked so that it is closer to TM3 than to TM1 in the kinked region [12] . For the cytoplasmic domain, the new image points out a larger surface for the coupling with effector molecules than was expected. This surface is formed by the spreading of intracellular loops along the surface of the plasma membrane and the lateral orientation of the C terminus [12] . For the extracellular domain, N-terminal and extracellular loop I (E-I), E-II, and E-III associate to form a compact structure [12] . The N-terminal may interact with E-I and E-III in several regions. E-II appears to have a very important role in forming the binding pocket of retinal. Upon activation by photons, the rearrangement of the helical bundle may be triggered and result in changes in the relative orientation of TM 3 and TM6, with a concomitant rotation of TM6, which may lead to the exposure of the G protein binding domain originally concealed in intracellular loop III [12] . Since the transmembrane domains are well conserved in each GPCR, we can speculate that the arrangement of transmembrane domains in chemokine receptor is very similar to that of rhodopsin. However, there are some specificities of chemokine receptor, such as an acidic N-terminal segment, a potential tyrosine sulfation motif in N terminus, a short basic third intracellular loop, and a cysteine in each of the four extracellular domains [6] . These unique features may impose a different structure of chemokine receptors in some profiles.
Hints from Mutagenesis and Computational Simulations
Mutagenesis and receptor computational simulations are the two methods used separately or combined to get the insight of chemokine receptors before their crystal structure is resolved. We have used random mutagenesis to get some information of the structure of CXCR4 [13] . Substitution of Asn-119 to different residues in TM3 of CXCR4 can confer constitutive activity to CXCR4 or make it have impaired function even in the presence of agonists, which suggests importance of TM3 in CXCR4 signaling. Consistent with our results, Marie et al [14] also find mutation of a similar Asn-113 to Ala in human B 2 bradykinin receptor also changes the receptor to highly constitutive state. Moreover, they also find this may be due to the disruptive interaction between Asn and a highly conserved Tyr in TM6. Altogether, as for rhodopsin, the relative orientation changes between TM3 and TM6 may count for the activation of CXCR4.
We further investigate the mechanisms involved in SDF-1 induced CXCR4 activation by using of computational simulations [15] . The entire simulations reveal the surface distribution features of electrostatic potentials and conformational "open-close" process of the receptor. It also shows an Arg188-Glu277 salt bridge plays an important role both for the extracellular domain conformational change and SDF-1α binding. Two binding sites for SDF-1 are mapped at the extracellular domain (Site 1) and inside the transmembrane domain (Site 2), which are composed of conserved residues. Electrostatic driven step of SDF-1α binding at site 1 results in a conformational change of the extracellular domain of CXCR4, subsequently promotes disruption of the Arg188-Glu277 switch and exposure of site 2. Arg8, Arg12 of SDF-1α are involved in this step. Then SDF-1α binds to CXCR4 at site 2 that is complemented mostly by the cooperation of TM3 and 6, which directs the receptor to its active conformation. Electrostatic interaction between Lys-1 in SDF-1 and Asp-262 plays a very important role in this step. Mutation of Lys-1 to other residues will result in the complete loss of binding affinity of SDF-1α with CXCR4 at site 2. Although small changes could be observed in TM 1, 2, 4, 5 and 7 because more hydrophobic packing makes them not very sensitive to the out-coming electrostatic stimulus, great changes happen to TM3 and 6. As the receptor reaches the active state of conformation, the electrostatic pulse will be transferred to the intracellular end of the relative helices, finally exposing the sites for G protein coupling in intracellular loops.
The approach combining protein structure modeling and site-directed mutagenesis has also been used to probe the structure of CCR5 and its interaction with chemokine ligands. These studies disclosed that certain residues in the N terminus, such as Tyr-10 and Lys-26, are important for ligand binding and signaling because substitution of these residues significantly decreases chemokine binding and signal transduction [16] . Moreover, a new feature is found in CCR5 that is different from rhodopsin. TM2 is shown to strongly interact with TM3 due to a highly conserved TXP motif in TM2 among chemokine receptors whereas a TM2 -TM1 interaction is found in rhodopsin [17] . Further investigation proves a cluster of aromatic residues at the extracellular border of TM2 and TM3 are involved in chemokine-induced activation [18] and Thr in the TXP motif is involved in maintenance of the receptor in the inactive state [19] .
Taking these pieces together, we can speculate the transmembrane helices of chemokine receptors are arranged in counterclockwise fashion and the movement of TM3 and TM6 will induce receptor activation. The interaction between TM2 and TM3 may affect the movement of TM3 and subsequent receptor activation. Moreover, the N terminus has an important role in ligand binding and receptor activation. The two steps binding and activation of receptor may exist in all of the chemokine receptors because several chemokines become antagonists after their N terminus are modified, which may disrupt the interaction between N terminus and receptor but still maintain their interaction through other sites in chemokines.
SIGNAL TRANSDUCTION MEDIATED BY CHEMO-KINE RECPEOTRS

Diversified Signals Transduced by Chemokine Receptors
As a member of G protein coupled receptors family, chemokine receptors mainly transduce signals through heterotrimeric G proteins. So far, about 20 mammalian G protein α subunits, 6 β units and 12 γ units have been identified [20] . Based on their primary sequences similarities, four main classes of G protein can be distinguished: Gs, which activates adenylyl cyclase; Gi, which inhibits adenylyl cyclase; Gq, which activates phospholipase C; and G12 and G13, which provide links between GPCRs and activation of small GTP-binding protein Rho [20] . G proteins are inactive in GDP-bound heterotrimeric form and are activated when the exchange of GDP to GTP in Gα subunits happens by interaction with agonist-activated GPCRs. The GTP-bound Gα subunit and dissociated Gβγ units initiate their signaling response by interacting with their individual effectors.
Intracellular signaling by chemokine receptors has been thought mainly mediated by pertussis toxin (PTX)-sensitive G proteins, esp. Gi protein [21] . By coupling to Gi protein, chemokine receptors can inhibit adenylyl cyclase. It has been shown that activation of chemokine receptors can inhibit forskolin-stimulated cyclic AMP accumulation in several cells, which is mediated by Gαi subunit [21] [22] [23] . Chemokine receptors can also activate phospholipase C (PLC) β2 [24] and PLCβ3 [25] which can generate two second messengers, diacylglyceride which can activate protein kinase C (PKC) and inositol 1,4,5 trisphophate which can induce calcium release from intracellular stores. In fact, calcium flux induced by chemokine receptors has been often used for measurement of their signaling. However, now it appears that the signals induced by chemokine receptors are much more complicated than this. The signals vary in different cells for the same receptor and vary in different chemokine receptors even for those that have very high identity.
There is growing evidence that chemokine receptors can couple to more G proteins other than PTX sensitive Gi protein. Although the calcium responses of microglial cells to SDF-1α are completely PTX sensitive, SDF-1α-mediated calcium response of astrocytes is partially inhibited by treatment with PTX, which means that other G proteins might also be involved in this process [26] . Directly coupling to other G proteins are also shown by co-transfection with chemokine receptors and Gα subunits in mammalian cells. CCR2 and CCR1 are able to couple to Gαi and Gαq but only CCR2 can couple to Gα16 in COS-7 cells [27] . However, in HEK293 cells, CCR2 fails to couple to Gα16 though it is still able to couple to Gαi and Gαq [27] . In contrast, CXCR1 is shown to couple to Gαi and Gα16 but fail to couple to Gαq in both cells [27] . Moreover, our results also show both CXCR4 and CCR5 can couple to another PTX sensitive G protein -Gαo in HEK293 cells [23] . Thus, chemokine receptors can couple to multiple G proteins but this coupling is cell specific and receptor specific.
In addition to activation of PLC, it is demonstrated that chemokine receptors can activate other phospholipases that exert other important biological effects. CC chemokines monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP) 1 alpha, and RANTES, are shown to cause rapid release of arachidonic acid in monocytes by activation of phospholipase A2 in a calcium dependent and PTX-sensitive manner [28] . Activation of phospholipase A2 is involved in monocyte polarization and chemotaxis induced by MCP-1 because this effect is blocked by inhibitors of phospholipase A2 [28] . Activation of phospholipase D by RANTES and IL-8 is also shown in Jurkat cells [29, 30] in a process requiring of GTP-binding proteins ARF and RhoA [29] . Interestingly, activation of phospholipase D by IL-8 is mediated by CXCR1 but not CXCR2 though these two receptors share high identity [30] . Phospholipase D activation is considered as an intermediate step in the activation of NADPH oxidase: an enzyme responsible for respiratory burst [30] .
The mitogen-activated protein kinase (MAPK) family are key enzymes at which many signal transduction pathways initiated by different extracellular stimuli converge. Four categories of MAPKs in mammalian cells have been reported to date: extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun NH2-terminal kinases (JNK), ERK5 (or BMK), and p38 MAPKs [20] . Several issues have addressed the activation of MAPKs by chemokine receptors. Again, it appears that activation of MAPKs vary in different receptors and in cells used to investigate. For example, although activation of CCR2 can induce activation of ERK both in murine peritoneal macrophages and human monocytes, activation of ERK in murine peritoneal macrophages can be blocked by PTX or by the inhibition of PI3K while in human monocytes it is largely insensitive to PTX and inhibition of PI3K but is PKC-dependent [31, 32] . It is reported CXCR4 can induce activation of ERK but not p38 MAPKs and JNK in murine pre-B lymphoma cell line transfected with human CXCR4 [33] . Nonetheless, we observed the activation of both ERK and p38 MAPKs in HEK293 cells transfected with human CXCR4 [34] . In addition, CCR5 induces activation of both p38 MAPKs and JNK in murine pre-B lymphoma cell line [35] . Activation of MAPKs is important for chemokines induced biological events. It is shown that inhibition of MCP-1-induced ERK activity is correlated with inhibition of actin polymerization, macrophage-mediated tumor cell cytotoxicity, tumor necrosis factor α transcription/production [31] . It is also shown activation of ERK, or p38 MAPKs is necessary for chemokine induced cell chemotaxis [32, 34] . The role of MAPKs in chemotaxis is still not very clear. But there is evidence that p38 MAPKs can phosphorylate heat shock protein p27 that acts as an Factin cap binding protein [36] . It has also been demonstrated that p38, but not PI3K (an important kinase for cell polarization), is necessary for cells migration after the determination of direction by initial stimulation with chemokine [37] .
Phosphorylation of different tyrosine kinase families and the kinase effectors by chemokine receptors has also been well noted [33, 35, 38, 39] . Following phosphorylation, these kinases and effectors often form a complex. Tyrosine phosphorylation induced by chemokine receptors may play an important role in cell proliferation and migration because many of them are involved in modulation of transcription factors or focal adhesion components. For example, activation of CXCR4 results in tyrosine phosphorylation and association of components of focal adhesion complexes such as the related adhesion focal tyrosine kinase (RAFTK or Pyk2), paxillin, and Crk [33] ; stimulation of CCR5 enhances phosphorylation of Pyk2 and subsequently activates the cytoskeletal protein paxillin and JNK [35] . Interestingly, it is shown that CCR2, CCR5 and CXCR4 can induce the activation of janus kinases (JAK) and phosphorylationactivation of latent monomeric signal transducers and activators of transcription proteins (STAT) [39] [40] [41] [42] . JAK/STAT signaling is likely a common feature of all cytokines that induce receptor aggregation after binding to their cognate cytokine receptors [43] . Dimmerization of CCR5, CXCR4 and CCR2 has also been observed after binding to their agonists [41, 42, 44] . Further more, activation of JAK/STAT appears independent of PTX sensitive protein and may be an initial step for chemokine receptors induced signaling [40, 42] . Further investigation is still needed to fully elucidate the activation of JAK/STAT and its effects. Activation of chemokine receptors also induces phosphorylation of the SH2 domain-containing cytoplasmic tyrosine phosphatase (SHP) subfamily members SHP1 and SHP2. The function of SHP in the chemokine receptors signaling still needs to be investigated. Previous study has shown inhibition of tyrosine phosphatase reduced MIP-1β induced cell migration [45] . But an enhanced effect SDF-1 induced chemotaxis has also been observed in leukocytes from SHP1 knocked-out mice [46] . Thus, several components, including different G proteins, second messengers, kinases, phosphatases, and transcription factors have been disclosed to be involved in the signaling of chemokine receptors. A concordance of these signaling pathways may be fine tuning of the biological functions of chemokine receptors.
Viral Proteins as Ligands for Chemokine Receptors
In addition to endogenous chemokines, several proteins encoded by virus can efficiently bind to chemokine receptors and have their biological events. Several viral chemokines have been reported, such as three CC chemokine homologs encoded by Kaposi's sarcoma-associated herpesvirus [47, 48] and CXC chemokine vCXC-1 encoded by cytomegavirus [49] . Viral chemokines can work as agonists or antagonists to modulate the function of leucocytes, for example, vCXC-1 is agonist for CXCR2 and may have the effect to recruit neutrophils to the place of cytomegovirus infection [49] ; vMIP-II is an antagonist for several chemokine receptors including CCR5, CCR3, and CXCR4, which inhibits the chemotaxis of freshly isolated human monocytes induced by chemokines [48] . Interestingly, human immunodeficiency virus (HIV) also encodes proteins that work as agonist or antagonist for chemokine receptors. The envelope protein (Env) of HIV had been originally thought to bind to CD4 and co-receptors such as CCR5 and CXCR4 to meditate the membrane fusion of virus and cells [50, 51] . The signals mediated by co-receptors are not necessary for virus entry [50, 51] . However, accumulating evidences have been shown at present that Env and gp120 can modulate cell function and virus replication by interaction with chemokine receptors and subsequently the signaling [52] . It has been shown that HIV-1 gp120 induces CCR5 or CXCR4 mediated complex and distinct signaling responses such as elevated intracellular calcium levels and activated K (Ca) and Cl (-) currents in primary macrophages [53] . The signaling induced by gp120 is necessary for some viruses' replication [52] . M-tropic (R5) induced chemotaxis of immature dendritic cells (iDCs) may facilitate dissemination of virus within an infected individual [54] . Moreover, apoptosis induced by interaction with HIV Env may play a role in HIV pathogenesis [52] . Another HIV encoded Tat protein also acts as agonist for CCR2 and CCR3 but not for CCR1, CCR4, and CCR5 [55] . In addition, it is antagonist for CXCR4 that selectively inhibits the entry and replication of X4, but not R5, virus in peripheral blood mononuclear cells [56] . Thus, the interaction between viral protein and chemokine receptors may influence viral infection, and spreading of some pathological syndrome. But further investigation is still needed to be employed to answer this question.
Modulation of Chemokine Receptors
The function of chemokine receptors is regulated at multiple levels. Post-transcriptional modifications have been shown to influence the trafficking and signaling of the receptors or the affinity of ligand bound to the receptors. It has been shown that palmitoylation of CCR5 is important for the surface expression of CCR5 and the duration of the functional response. The non-palmitoylated CCR5 mutant is sequestrated in intracellular biosynthetic compartments with reduced response to agonist as measured by a microphysiometer and [
35 S]GTPγS binding [57] . Modification of extracellular domains has been shown to affect the affinity or specificity of receptors bound to their cognate ligands. There are two potential N-glycosylation sites in CXCR4 and CXCR4 undergoes N-glycosylation. Mutation of either of its N-glycosylation sites severely impairs binding affinity of CXCR4 to SDF-1 and double mutant receptor shows little binding activity [58] . Interestingly, N-glycosylation of CXCR4 also appears necessary for its specificity to T-tropic HIV because the removal of the N-linked glycosylation sites in CXCR4 potentially allows CXCR4 gaining the ability to serve as co-receptor for R5 HIV-1 strains [59] . Nglycosylation is also observed in CXCR2, which is not necessary for receptor trafficking and signaling but have the function to protect CXCR2 from proteolytic attack [60] . CCR5 does not undergo N-glycosylation but is modified by O-glycosylation [61] . The exact role of O-glycosylation of CCR5 still needs further investigation. A potential tyrosine sulfation motif in N terminus has been found among chemokine receptors [6] . There is evidence that tyrosine sulfation does occur and has important roles in the function of chemokine receptors. Sulfated tyrosines contribute to the binding of CCR5 to its ligands and to the co-receptor activity of CCR5 [61] . CXCR4 is also sulfated, which contributes substantially to the ability of CXCR4 to bind its ligand. However, unlike CCR5, tyrosine sulfation is not important for it to serve as HIV-1 co-receptor [62] .
Modulation of chemokine receptors also happens in response to the stimulation by agonist. Repeated or long time exposure to agonist could damper the response of the receptor to the agonist, which is called desensitization. Mechanisms of desensitization are not fully disclosed but receptor phosphorylation and internalization are the important causes [63] . Upon agonist stimulation, the receptors are phosphorylated by G protein-coupled receptor kinase (GRK), followed by binding of arrestin which serves to uncouple the receptor from G protein and to mediate receptor internalization via clathrin-coated pits [63] . Phosphorylation and internalization of chemokine receptors are well observed. Phosphorylation and internalization appear to be related but independent process because mutants lacking of receptor phosphorylation internalized normally. A carboxyl terminus-truncated mutant of CXCR2 (331T) continues to undergo ligand-induced internalization although it lacks agonist-induced phosphorylation [64] . Moreover, CXCR4 with cytoplasmic tail deletion is internalized when stimulated with SDF-1 although phosphorylation is not observed [25] . However, receptor phosphorylation may be the major reason for acute receptor desensitization, in which the C-terminal of the receptor is largely involved. Enhanced signaling after deletion of the Cterminal has been observed in several chemokine receptors [25, 65, 66] . Regulation of the receptor desensitization by β-arresting also appears highly dependent on the C-terminal of the receptor because receptor desensitization mediated by β-arrestin is not observed in a C-terminal truncated CXCR4 although it still can bind to β-arresin [67] . In addition to GRK induced receptor phosphorylation, PKC induced receptor phosphorylation is observed [25] . However, PKC may account for the hetero-phosphorylation and desensitization but only partially involved in agonist induced homophosphorylation and desensitization. Inhibition of PKC only partially decreases SDF-1-induced CXCR4 phosphorylation [25] but prevents phosphorylation of CXCR4 induced by CXCR1 activation [65] . N-formyl-methionyl-leucylphenylalanine also rapidly induces a PKC-mediated serine phosphorylation of the CCR5 [68] . The different roles of GRK and PKC in response to agonists may be fine tuning of the receptor mediated signaling network.
Although receptor internalization may also be involved in its desensitization, there is accumulating evidence that its role is more complicated and this process is differently regulated for different receptors or by different protein kinases. It is shown that β-arrestin can enhance SDF-1 induced receptor internalization, ERK and p38 MAPKs activation and chemotaxis [34, 67] . CXCR2 mutants with impaired agonist-induced receptor sequestration are also greatly impaired in ligand-mediated chemotaxis [64] . After internalization, receptors may be recycled to the plasma or be degraded. CCR5 undergoes rapid endocytosis after stimulated by agonist but is recycled to the plasma immediately whereas CXCR4 is degraded and poorly recycled after stimulation by SDF-1 [69, 70] . However, endocytosis of CXCR4 induced by activation of PKC is recycled well [71] . The fate of the receptor seems dependent on where it is sorted after internalization. Once the receptor is directed to lysosome, it will be degraded. For example, CCR5 is present in late endosomes but CXCR4 is sorted to lysosomes after agonist stimulation [69, 70] . Consistently, CXCR4 internalized by activation of PKC is also present in late endosomes [71] . Mechanisms for the different sorting of the receptors are not very clear. But agonist-promoted ubiquitination of the receptor may have a specific role in sorting endocytosed chemokine receptors to lysosomes [72] . Moreover, Rab proteins are involved in the regulation of intracellular trafficking of the receptor [73] . The C-terminal tail of the receptor has important role in the process of internalization. A dileucine motif in C-terminal tail is shown to be important for endocytosis of receptor but not for ubiquitination [72] . Binding of the C-terminal tail to protein phosphatase 2A also suggests C-terminal tail has a critical role in dephosphorylation of the receptor after it is internalized [74] . Chemokine receptors vary a lot in the Ctail, which may account for different regulation of the receptors after receptor internalization.
The function of chemokine receptors can also be regulated by interaction with other proteins. In addition to a ligandmediated homodimerization process required for Ca2+ flux and chemotaxis [44] , chemokine receptors also undergo heterodimerization in response to the stimulation of agonist [75] . Interestingly, heterodimerization results in specific functions of the receptors, such as lower threshold when both of the agonists are used together, activation of different G protein, and different biological effects compared with the individual receptor alone [75] . Interaction of chemokine receptors with other surface proteins is also found. It is shown that CCR5 can directly associate with the extracellular portion of CD4 and the function of CD4-CCR5 complex is different from CCR5 alone [76] . Although the CD4-CCR5 complex has decreased affinity for MIP-1β, it has enhanced G-protein signaling as compared with CCR5 alone. Moreover, activation of CD4 can enhance CCR5 mediated G protein activation. Interaction with other proteins may endow chemokine receptors with specific functions in its physiological roles. It also suggests a concord regulation of chemokine receptor by cytokine network may happen in vivo.
PHYSIOLOGICAL AND PATHOLOGICAL ROLES OF CHEMOKINE RECEPTORS
Several reviews [2, 4, 6, [77] [78] have thoroughly described these aspects and we will only mention them briefly here. By interacting with their individual chemokine receptors, chemokines function as guide for cell migration. Basically, inducible chemokines promote inflammation through recruitment of leukocyte to areas of tissue injury and constitutive chemokines are responsible for basal leukocyte trafficking and forming the architecture of secondary lymphoid organs [5, 78] . Moreover, as for CX 3 CL1, it also works as an adhesion molecule when it interacts with its receptor CX 3 CR1 [6] . However, the functions of chemokines are now found much beyond this, they also play a central role in 1) homing of hematopoietic, neuronal, endothelial cells and primordial germ cells [79] [80] [81] [82] [83] ; 2) embryologic development of the cardiovascular and nervous systems [79] [80] [81] [82] ; 3) guidance cues for cerebellar axon pathfinding [84] . More importantly, some chemokine receptors, such as CCR5 and CXCR4, are found to serve as indispensable co-receptors for HIV entry to cells and individuals carrying CCR5-delta 32 alleles are resistant to HIV-1 infection [85] . Moreover, chemokine receptors are also found to have an important role in proliferation and metastasis of cancer cells [86] . A very recent paper confirms this and shows directly up-regulating the expression of CXCR4 by NF-κB promotes breast cancer cell migration and metastasis [87] .
Since the function of chemokines is much related with leukocyte chemotaxis, it is not surprising that the overexpression of chemokines or losing the control of the expression of chemokines will lead to excessive recruitment of leukocyte that ultimately induces both acute and chronic inflammatory disorders. From the data of knockout mice and using blocking reagents, such as antibodies and antagonists, to block the function of chemokines and chemokines receptors, it is implicated that chemokines are involved in autoimmune disease such as multiple sclerosis, graft rejection, infection, inflammation or allergy, neopalsia and vascular [4, 77, 78] . However, the exact roles of chemokine receptors in inflaminatory and immunary disease still need to be further investigated because the redundancy and overlap roles of chemokines and chemokine receptors make it hard to get a good picture by only disrupting one receptor. It may be help in the future to use combined antagonists targeting several related chemokines at a time to see their roles.
TARGETING CHEMOKINE RECEPTORS FOR DRUGS
The important roles of chemokine receptors in physiology and pathology make them serve as a very important target for drug discovery. For this purpose, high through-put screening systems, probably combined with computational drug screening methods, are applied for screening to get more leading compounds targeting chemokine receptors. Reagents that have the functions to modulate chemokine receptors are developed and some of them are already in clinic trials.
Blockade of Chemokine Receptors by Antagonists and Antibodies
Several recent reviews have given a thorough picture for this topic [6, 78, 88, 89] . Briefly, a lot of antagonists and antibodies targeting different chemokine receptors have been developed (see Table 1 ). They have been used to investigate the functions of chemokine receptors. Moreover, several of them are already in clinical trial. The antagonists belong to two categories: small molecular weight chemical compounds and peptides (including small protein). As for drug developments, it will be appealing to get as much oral available small molecular weight oral compounds instead of getting peptides.
Drug Screening Technology Based on the Signaling of Chemokine Receptors
Theoretically all of the signals elicited by chemokine receptors can be used as monitors for drug screening because agonists will elicit the signals while antagonists will block the signals induced by agonists. However, the signals used practically are those that have high sensitivity and are specific to the receptor tested. Moreover, the assays should be fit for 96 wells, 384 wells, and 1536 wells.
Receptor binding is widely used to screen out the compounds that have the ability to displace the knownligand from the receptor. However, it is nonfunctional assay that does not allow for differentiation between receptor agonists and antagonists. The more appealing assays are function assays that can illustrate the characters of the compounds.
It is frequently used as a specific signal to detect the calcium flux induced by chemokine receptors. With instruments developed, such as FLIPR (Molecular Devices), it is able to detect calcium flux kinetically in whole cells that are seeded in plates. Fluo-3 and Fluo-4 are dyes often used in this assay because they can emit fluorescence when bound to calcium and there is a great difference in their excitation and emission wavelength so that the background is low. This assay is successfully used to detect the specificity of AMD3100 and make the conclusion that it is a very specific antagonist to CXCR4 [90] . In addition, calcium-dependent activation of aequorin bioluminescence is also a good tool to detect calcium flux [17, 18] .
The genes transcription induced by GPCRs can be applied to detect the response of GPCRs to their cognate agonists. For example, A reporter gene that is down stream of the cyclic AMP response element can be used to detect the activation of Gs coupled DP prostanoid receptor because the activated receptor can induce the activation of protein kinase A, which can subsequently activate the transcription factor CREB (cyclic AMP response element binding protein) [91] . However, as receptors that mainly couple to Gi protein, the gene transcription induced by chemokines receptors is neither very strong nor specific. ERK-induced gene expression can be used to detect the response of Gi coupled receptors [92] . But since several stimuli other than GPCRs can induce robust activation of ERK, the signal of this system will be easily disturbed by noises. However, this problem can be overcome by using a yeast-GPCR expression system [13] . The response of mammalian Gi coupled GPCRs can be functionally coupled to the yeast α-or a-factor mating pheromones signaling pathway by using a chimera yeast Gpa1 protein that contains the last five residues of human Giα subunit. Human CXCR4 have been successfully expressed in yeast and it can respond to agonists and antagonists very well by detecting the expression of reporter gene β-galactosidase. The ratio of signal to noise is very high. This system can be used for high-throughput screen for antagonists especially when using the constitutively active receptor.
The activation of G protein is a very appealing part of signaling components used to detect the function of GPCRs because it reflects the function of receptors but with less amplification of the signals and regulation by other cellular processes than other signaling events (such as regulation of gene expression) [93] . The GTPγS binding assay has been used to detect the activation of Gi protein for a long time. The detection of activation of Gq or Gs has been restricted by poor signal to background [93] . However, now this problem can be overcome by immuno-enrichment and the use of GPCR-G-protein fusions, which broaden this assay to be fit to the detection of the activation of all the GPCRs [93] . Chemokine receptors can activate G proteins very well. We have applied this assay successfully to screen out the agonists and antagonists to CCR1, CXCR4 and CCR5 (unpublished data). It proves to be a high signal to noise assay and could be tolerated to 1% DMSO. Moreover, it can be used to discriminate full, partial and inverse agonist [13, 94] , which is very important to drug development because agonist of chemokines receptors may have more side effects when used for treatment.
Constitutively Active Receptor: A Useful Tool for Drug Screening and Discrimination
According to current models for the mechanism of GPCRs activation, receptors exist in a dynamic equilibrium between R (inactive) and R* (active) states [95] . For most of GPCRs, under physiologic conditions, the R conformation is predominant and the R* conformation is favored by receptor engagement by agonist. However, GPCRs can be endowed with agonist independent activity (constitutively activity) by mutations that release the constraints in receptor or form new interactions in the receptor to maintain its R* state [95] . Moreover, some GPCRs can get detectable signals in vivo or by overexpression because they have a large percent R* state naturally [94, 95] . Constitutively active GPCRs are very useful tool in drug screening because they have the following advantages: 1) they can be applied to discriminate agonist, partial agonist and inverse agonist because their signals can go two ways, that is, increasing the basal activity by agonist and decreasing the basal activity by inverse agonists [13, 94, 95] ; 2) because most of constitutively active receptors are more sensitive to stimuli, it is possible to get the low activity ligands that might be missed when using wild type receptors; 3) they can be used for screening out agonists and inverse agonists even for orphan GPCRs. In turn, these ligands will be good tools to discover the function of orphan GPCRs in vivo [95] ; 4) it will save money when the agonists for the receptor are expensive, for example, chemokines.
We reported the first constitutively active chemokines receptor: constitutively active CXCR4 mutants (CAMs) and have used the receptor to discriminate the antagonists [13] . We find three widely used CXCR4 antagonists belonging to two categories: AMD3100 and ALX40-4C are partial week agonists but T140 is inverse agonist because AMD3100 and ALX40-4C can enhance the basal activity of CAMs while T140 can decrease the basal activity. This result is very important for drug development because it may be one of the possible reasons that AMD3100 mobilizes hematopoietic progenitor cells in vivo [96] . In addition, the partial agonist activity would clearly preclude the use of these agents as antagonists of metastatic behavior in mammary carcinoma, because stimulation of CXCR4 on the surface of tumor cells could increase dissemination. Moreover, AMD3100 and ALX40-4C may influence the infection of target cells by R5 viruses or stimulate replication during latency in vivo due to activation of CXCR4 [52] . Recently, constitutively active CCR5 and CCR2 mutants have also been engineered, which will provide a useful tool for the development of the inverse agonists for these two receptors [19] . CCR3 is a naturally occurring constitutively active chemokine receptor reported to date. It has been used successfully to discriminate the different ligands of CCR3. Banyu (I) is identified as an inverse agonist for CCR3; CCL18 and I-TAC (interferoninducible T cell a-chemoattractant) are neutral antagonists; eotaxin, eotaxin-2 and MCP-4 are full agonists; and eotaxin-3, MCP-3, RANTES, vMIP-I and vMIP-II are partial agonists for CCR3 [94] .
Getting Drugs from Nature
Several traditional Chinese medicines have been used to treat inflammations and immunodiseases for centuries. It is possible that these medicines contain natural substance that can modulate the function of chemokine receptors. The natural plants, animals, and microorganisms should provide another source for screen out the ligands of chemokine receptors in addition to the synthesis of chemical compounds.
In fact, there are examples for this. T22, a derivative of horseshoe crab blood cell-derived peptide with 18 amino acid residues, is shown to be a small molecule CXCR4 antagonist and specifically inhibits T-tropic HIV-1 entry to cells [97] . Moreover, a derivative of T22, T140, is the most potent specific CXCR4 antagonist to date [98] . Shikonin, a chemically characterized component of traditional Chinese herbal medicine, has been shown to be a CCR1 antagonist with no cross-react to CCR5, CXCR4 and CXCR3 [99] . Interestingly, Trichosanthin (TCS), an active protein component isolated from a traditional Chinese medicinal herb Trichosanthes kirilowii, is also found to be modulator for chemokine receptors but not antagonist [100] . Our study demonstrates that TCS significantly augmented chemokinestimulated activation of chemokine receptors CCR5 and CXCR4 as well as CCR1, CCR2B, CCR3, and CCR4. In addition, the effects of TCS may be through its interaction with chemokine receptors because a mutant TCS with 4,000-fold lower ribosome-inactivating activity showed similar augmentation activity as wild-type TCS. Moreover, we also provide clear evidences to show the binding of TCS to chemokine receptors. With more and more components isolated, it is possible to screen out more ligands for chemokine receptors from nature medicines and used for treatment.
Intrakine and RNAi: Useful Tools for Knocking Down Chemokine Receptors
Given the important roles of chemokine receptors in pathology, it is reasonable to speculate that it would affect the pathology progress by knocking down the chemokine receptors in cell surface. For instance, HIV can't infect cells without the aid of chemokine receptors [85] , esp. CCR5 and CXCR4. Several methods have been developed for this purpose. The two that seem very successful are intrakine and RNAi.
"Intrakine" is genetically modified by intracellular chemokines that have been linked with an endoplasmic reticulum (ER) retention signal sequence (KDEL) on their carboxyl termini so that it can be retained in ER while maintains the function of binding to its cognate receptor [101] . It has been used to decrease the surface expression of chemokine receptors by retaining the receptor in ER and subsequently degradation. A RANTES intrakine has been shown to decrease the surface expression of CCR5, as well as CCR1 and CCR3 in human T-lymphocytes and protect them from infection by a variety of R5-tropic HIV-1 strains [102] . A SDF-1 intrakine has also been introduced into lymphocytes. Lymphocytes expressing this intracellular chemokine are immune to T-tropic virus infection but retain normal biological features [101] . Thus the intrakine shows elegant blockade of the surface expression of chemokine receptors and can be used for gene therapy.
RNA interference (RNAi) technology is an efficient and specific tool for silencing gene expression. Several genes have been knocked down to see their effects in vivo [34, 103, 104] . Recently, the CCR5 expressed in the peripheral blood T lymphocytes has been successfully knocked down by introducing RNAi against CCR5 [103] . Importantly, it is shown that blocking CCR5 expression by siRNAs protects the lymphocyte populations from M-tropic HIV-1 virus infection while only a minimal effect on infection by a Ttropic virus [103] . Another report also shows RNAi directed to CXCR4 and CCR5 suppresses the expression of CXCR4 and CCR5 respectively and the acute infection of CXCR4+ or CCR5+ U87-CD4+ cells by X4 or R5 HIV-1 strains is effectively blocked [104] . With the development of RNAi delivery systems, we could expect to treat inflammations and infectious disease by introducing RNAis against chemokine receptors in vivo.
Computational Simulations: A Probable Good Tool for Drug Discovery
In addition to being used to obtain insight into mechanisms governing receptors activation, computational simulated ligand docking also provide a powerful tool to gain the knowledge of the interaction between receptors and antagonists. It may be used to acquire hits by virtual screening of the compounds library. In fact, this technology has been employed to get antagonists for the thyroid hormone receptor based on the computer model of the thyroid hormone receptor ligand-binding domain and using a virtual screening algorithm [105] . Two rounds for screening are applied. The compounds selected from the first round are tested by use of cell-based assay. Then the second round of selection is applied based on a small virtual library of compounds derived from the highest affinity antagonist . New compounds with predicted increased antagonist activity are identified screened out from the second round and they show a nice biological activity in cell-based assay.
However, so far, there are still no successful examples of using the modeled chemokine receptors for drug screening. Several models based on the crystal structure of rhodopsin have been given to chemokine receptors, such as CCR2b, CCR5 and CXCR4, and some known antagonists have been docked in the simulated binding pocket [15, [106] [107] [108] . We have tried to dock TAK779, an antagonist of CCR5, to the 3D-structrual model of CCR5 that is constructed using the 3D-model of frog rhodopsin as a template. We propose the binding pocket is situated in TM 3, 5, 6, and 7. We also predict O 1 , N 7 , N 17 , and O 19 of TAK779 are the active center of TAK779 [107] . However, another model for TAK779 gives different results. In that model, TAK779 binds to CCR5 in the cavity formed by TM 1, 2, 3, and 7 with additional interactions with helices 5 and 6 [108] . These discrepancies may be due to different programs used. Thus it points out the necessity to use as much biological data of the receptor as possible to fine-tune the structure of the receptors before it can be employed for virtual screen. It may be good to model the receptors based on the data from high throughput screening. Then the models and simulation programs should provide great help in the design of the new compounds with higher specificity to the receptors. 
